241 related articles for article (PubMed ID: 34150652)
1. Clinical Benefits and Safety of FMS-Like Tyrosine Kinase 3 Inhibitors in Various Treatment Stages of Acute Myeloid Leukemia: A Systematic Review, Meta-Analysis, and Network Meta-Analysis.
Xu Q; He S; Yu L
Front Oncol; 2021; 11():686013. PubMed ID: 34150652
[TBL] [Abstract][Full Text] [Related]
2. FLT3 inhibitors as maintenance therapy post allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia patients with FLT3 mutations: A meta-analysis.
Fei X; Zhang S; Gu J; Wang J
Cancer Med; 2023 Mar; 12(6):6877-6888. PubMed ID: 36411731
[TBL] [Abstract][Full Text] [Related]
3. Clinical Outcomes in Patients with FLT3-ITD-Mutated Relapsed/Refractory Acute Myelogenous Leukemia Undergoing Hematopoietic Stem Cell Transplantation after Quizartinib or Salvage Chemotherapy in the QuANTUM-R Trial.
Ganguly S; Cortes JE; Krämer A; Levis MJ; Martinelli G; Perl AE; Russell NH; Arunachalam M; Santos CD; Gammon G; Lesegretain A; Mires DE; Pham H; Wang Y; Khaled SK
Transplant Cell Ther; 2021 Feb; 27(2):153-162. PubMed ID: 33017662
[TBL] [Abstract][Full Text] [Related]
4. Hypomethylating Agents and FLT3 Inhibitors As Maintenance Treatment for Acute Myeloid Leukemia and Myelodysplastic Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation-A Systematic Review and Meta-Analysis.
Bewersdorf JP; Allen C; Mirza AS; Grimshaw AA; Giri S; Podoltsev NA; Gowda L; Cho C; Tallman MS; Zeidan AM; Stahl M
Transplant Cell Ther; 2021 Dec; 27(12):997.e1-997.e11. PubMed ID: 34551341
[TBL] [Abstract][Full Text] [Related]
5. The effect of the detection of minimal residual disease for the prognosis and the choice of post-remission therapy of intermediate-risk acute myeloid leukemia without FLT3-ITD, NPM1 and biallelic CEBPA mutations.
Zheng WS; Hu YL; Guan LX; Peng B; Wang SY
Hematology; 2021 Dec; 26(1):179-185. PubMed ID: 33594943
[TBL] [Abstract][Full Text] [Related]
6. FLT3-ITD Allelic Ratio and NPM1 Mutation Do Not Impact Outcomes in Acute Myeloid Leukemia Patients with FLT3-ITD after Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Propensity Score- Matching Study.
Zhou C; Zheng F; Xu L; Zhang X; Chang Y; Mo X; Sun Y; Huang X; Wang Y
Transplant Cell Ther; 2023 Jul; 29(7):456.e1-456.e11. PubMed ID: 37028555
[TBL] [Abstract][Full Text] [Related]
7. Combination of KIT and FLT3-ITD mutation status with minimal residual disease levels guides treatment strategy for adult patients with inv(16) acute myeloid leukemia in first complete remission.
Wang J; Dao FT; Wang Y; Jiang H; Xu LP; Zhao XS; Zhang XH; Liu KY; Huang XJ; Jiang Q; Qin YZ
Hematol Oncol; 2022 Oct; 40(4):724-733. PubMed ID: 35531760
[TBL] [Abstract][Full Text] [Related]
8. Salvage therapy using FLT3 inhibitors may improve long-term outcome of relapsed or refractory AML in patients with FLT3-ITD.
Takahashi K; Kantarjian H; Pemmaraju N; Andreeff M; Borthakur G; Faderl S; Garcia-Manero G; Pierce S; Luthra R; Cardenas-Turanzas M; Estrov Z; Ravandi F; Cortes J
Br J Haematol; 2013 Jun; 161(5):659-666. PubMed ID: 23530930
[TBL] [Abstract][Full Text] [Related]
9. [Influence of FLT3-ITD Mutation and ITD Length on the Outcome on Patients with Acute Myeloid Leukemia].
Chen F; Jiang XJ; Yin CX; Zhong QX; Jiang L; Yu GP; Sun J; Meng FY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Jun; 26(3):678-683. PubMed ID: 29950203
[TBL] [Abstract][Full Text] [Related]
10. Is allogeneic transplantation really the best treatment for FLT3/ITD-positive acute myeloid leukemia? A systematic review.
Ma Y; Wu Y; Shen Z; Zhang X; Zeng D; Kong P
Clin Transplant; 2015 Feb; 29(2):149-60. PubMed ID: 25430616
[TBL] [Abstract][Full Text] [Related]
11. Which FLT3 Inhibitor for Treatment of AML?
Senapati J; Kadia TM
Curr Treat Options Oncol; 2022 Mar; 23(3):359-380. PubMed ID: 35258791
[TBL] [Abstract][Full Text] [Related]
12. Outcome of FLT3-ITD-positive acute myeloid leukemia: impact of allogeneic stem cell transplantation and tyrosine kinase inhibitor treatment.
Fleischmann M; Schnetzke U; Schrenk KG; Schmidt V; Sayer HG; Hilgendorf I; Hochhaus A; Scholl S
J Cancer Res Clin Oncol; 2017 Feb; 143(2):337-345. PubMed ID: 27778197
[TBL] [Abstract][Full Text] [Related]
13. Outcomes in Patients with FLT3-Mutated Relapsed/ Refractory Acute Myelogenous Leukemia Who Underwent Transplantation in the Phase 3 ADMIRAL Trial of Gilteritinib versus Salvage Chemotherapy.
Perl AE; Larson RA; Podoltsev NA; Strickland S; Wang ES; Atallah E; Schiller GJ; Martinelli G; Neubauer A; Sierra J; Montesinos P; Recher C; Yoon SS; Maeda Y; Hosono N; Onozawa M; Kato T; Kim HJ; Hasabou N; Nuthethi R; Tiu R; Levis MJ
Transplant Cell Ther; 2023 Apr; 29(4):265.e1-265.e10. PubMed ID: 36526260
[TBL] [Abstract][Full Text] [Related]
14. Clinical Benefits and Safety of Gemtuzumab Ozogamicin in Treating Acute Myeloid Leukemia in Various Subgroups: An Updated Systematic Review, Meta-Analysis, and Network Meta-Analysis.
Xu Q; He S; Yu L
Front Immunol; 2021; 12():683595. PubMed ID: 34484181
[TBL] [Abstract][Full Text] [Related]
15. Use of FLT3 inhibitors in acute myeloid leukemia remission induction or salvage therapy: systematic review and meta-analysis.
Yang M; Zhao J; Liu T; Yang X; Wei H; Xu W; Xiao J
Cancer Manag Res; 2018; 10():2635-2652. PubMed ID: 30147364
[TBL] [Abstract][Full Text] [Related]
16. Impact of FLT3-ITD allele ratio and ITD length on therapeutic outcome in cytogenetically normal AML patients without NPM1 mutation.
Chen F; Sun J; Yin C; Cheng J; Ni J; Jiang L; Wang Q; Yu G; Wei Y; Liu X; Sun J; Carter BZ; Jiang X
Bone Marrow Transplant; 2020 Apr; 55(4):740-748. PubMed ID: 31645666
[TBL] [Abstract][Full Text] [Related]
17. Impact of FLT3-ITD Mutation Status and Its Ratio in a Cohort of 2901 Patients Undergoing Upfront Intensive Chemotherapy: A PETHEMA Registry Study.
Ayala R; Carreño-Tarragona G; Barragán E; Boluda B; Larráyoz MJ; Chillón MC; Carrillo-Cruz E; Bilbao C; Sánchez-García J; Bernal T; Martinez-Cuadron D; Gil C; Serrano J; Rodriguez-Medina C; Bergua J; Pérez-Simón JA; Calbacho M; Alonso-Domínguez JM; Labrador J; Tormo M; Amigo ML; Herrera-Puente P; Rapado I; Sargas C; Vazquez I; Calasanz MJ; Gomez-Casares T; García-Sanz R; Sanz MA; Martínez-López J; Montesinos P
Cancers (Basel); 2022 Nov; 14(23):. PubMed ID: 36497281
[TBL] [Abstract][Full Text] [Related]
18. FLT3-ITD with DNMT3A R882 double mutation is a poor prognostic factor in Chinese patients with acute myeloid leukemia after chemotherapy or allogeneic hematopoietic stem cell transplantation.
Tang S; Shen H; Mao X; Dai H; Zhu X; Xue S; Ding Z; Lu J; Wu D; Tang X
Int J Hematol; 2017 Oct; 106(4):552-561. PubMed ID: 28616699
[TBL] [Abstract][Full Text] [Related]
19. Acute myeloid leukemia patient with
Huang Y; Hu J; Lu T; Luo Y; Shi J; Wu W; Han X; Zheng W; He J; Cai Z; Wei G; Huang H; Sun J
Cancer Manag Res; 2019; 11():4129-4142. PubMed ID: 31190985
[No Abstract] [Full Text] [Related]
20. Allogeneic Stem Cell Transplantation Improves Survival in Patients with Acute Myeloid Leukemia Characterized by a High Allelic Ratio of Mutant FLT3-ITD.
Ho AD; Schetelig J; Bochtler T; Schaich M; Schäfer-Eckart K; Hänel M; Rösler W; Einsele H; Kaufmann M; Serve H; Berdel WE; Stelljes M; Mayer J; Reichle A; Baldus CD; Schmitz N; Kramer M; Röllig C; Bornhäuser M; Thiede C; Ehninger G;
Biol Blood Marrow Transplant; 2016 Mar; 22(3):462-9. PubMed ID: 26551637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
